Laurie McLaughlin1,2, Laura Clarke1,2, Elham Khalilidehkordi1,2, Helmut Butzkueven3, Bruce Taylor4, Simon A Broadley5,6. 1. School of Medicine, Gold Coast Campus, Griffith University, Gold Coast, QLD, 4222, Australia. 2. Department of Neurology, Gold Coast University, Hospital, Southport, QLD, Australia. 3. MS and Neuroimmunology Service, Dept of Neuroscience, Central Clinical School, Alfred Health, Monash University, Melbourne, VIC, Australia. 4. Menzies Research Institute Tasmania, University of Tasmania, Hobart, TAS, Australia. 5. School of Medicine, Gold Coast Campus, Griffith University, Gold Coast, QLD, 4222, Australia. simon.broadley@griffith.edu.au. 6. Department of Neurology, Gold Coast University, Hospital, Southport, QLD, Australia. simon.broadley@griffith.edu.au.
Abstract
OBJECTIVE: There is an association between latitude, relative vitamin D deficiency and risk of multiple sclerosis (MS), and an association between vitamin D and disease progression. We have performed a meta-analysis with the aim of investigating the role of therapeutic vitamin D in MS. METHODS: A systematic search of databases was performed to identify clinical trials assessing vitamin D in patients with relapsing-remitting MS. Studies were selected based on inclusion and exclusion criteria. Analysis was performed using RevMan 5.3 software. RESULTS: Twelve studies involving 950 patients were included in the final analysis. Studies were divided into four groups because of heterogeneity in study design. Studies were judged to be at low or unclear risk of bias, except in three studies, and this was confirmed by funnel plots. No statistically significant difference was seen for any of the outcome measures. There were non-significant trends in favour of vitamin D for all outcome measures, particularly when only placebo-controlled studies were included. Dose comparison studies showed a significant increase in annualised relapse rate (mean difference 0.15 [95%CI 0.01-0.30]) and non-significant trends of increased Expanded Disability Status Scale and gadolinium-enhancing lesions for the higher-dose arms. CONCLUSION: These findings suggest that vitamin D supplementation may have a therapeutic role in the treatment of MS. However, there is uncertainty with regard to the most appropriate dose, with high doses potentially being associated with worse outcomes. There remains the need for further well-performed randomised, dose-ranging, placebo-controlled trials of vitamin D in MS.
OBJECTIVE: There is an association between latitude, relative vitamin D deficiency and risk of multiple sclerosis (MS), and an association between vitamin D and disease progression. We have performed a meta-analysis with the aim of investigating the role of therapeutic vitamin D in MS. METHODS: A systematic search of databases was performed to identify clinical trials assessing vitamin D in patients with relapsing-remitting MS. Studies were selected based on inclusion and exclusion criteria. Analysis was performed using RevMan 5.3 software. RESULTS: Twelve studies involving 950 patients were included in the final analysis. Studies were divided into four groups because of heterogeneity in study design. Studies were judged to be at low or unclear risk of bias, except in three studies, and this was confirmed by funnel plots. No statistically significant difference was seen for any of the outcome measures. There were non-significant trends in favour of vitamin D for all outcome measures, particularly when only placebo-controlled studies were included. Dose comparison studies showed a significant increase in annualised relapse rate (mean difference 0.15 [95%CI 0.01-0.30]) and non-significant trends of increased Expanded Disability Status Scale and gadolinium-enhancing lesions for the higher-dose arms. CONCLUSION: These findings suggest that vitamin D supplementation may have a therapeutic role in the treatment of MS. However, there is uncertainty with regard to the most appropriate dose, with high doses potentially being associated with worse outcomes. There remains the need for further well-performed randomised, dose-ranging, placebo-controlled trials of vitamin D in MS.
Entities:
Keywords:
Meta-analysis; Multiple sclerosis; Treatment; Vitamin D
Authors: M S Stein; Y Liu; O M Gray; J E Baker; S C Kolbe; M R Ditchfield; G F Egan; P J Mitchell; L C Harrison; H Butzkueven; T J Kilpatrick Journal: Neurology Date: 2011-10-25 Impact factor: 9.910
Authors: Martin Hewison; Fiona Burke; Katie N Evans; David A Lammas; David M Sansom; Philip Liu; Robert L Modlin; John S Adams Journal: J Steroid Biochem Mol Biol Date: 2007-03 Impact factor: 4.292
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: Lawrence T C Ong; Grant P Parnell; Kelly Veale; Graeme J Stewart; Christopher Liddle; David R Booth Journal: Genes Immun Date: 2020-10-09 Impact factor: 2.676
Authors: Marni E Shoemaker; Linda M Huynh; Cory M Smith; Vikkie A Mustad; Maria O Duarte; Joel T Cramer Journal: Top Clin Nutr Date: 2022-06-22 Impact factor: 0.441
Authors: Arianna Di Stadio; Antonio Della Volpe; Fiammetta M Korsch; Antonietta De Lucia; Massimo Ralli; Francesco Martines; Giampietro Ricci Journal: Nutrients Date: 2020-06-02 Impact factor: 5.717
Authors: Friederike Maretzke; Angela Bechthold; Sarah Egert; Jana B Ernst; Debora Melo van Lent; Stefan Pilz; Jörg Reichrath; Gabriele I Stangl; Peter Stehle; Dorothee Volkert; Michael Wagner; Julia Waizenegger; Armin Zittermann; Jakob Linseisen Journal: Nutrients Date: 2020-03-31 Impact factor: 5.717
Authors: A Giustina; R A Adler; N Binkley; J Bollerslev; R Bouillon; B Dawson-Hughes; P R Ebeling; D Feldman; A M Formenti; M Lazaretti-Castro; C Marcocci; R Rizzoli; C T Sempos; J P Bilezikian Journal: Rev Endocr Metab Disord Date: 2020-03 Impact factor: 6.514